Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB (OMX: IRLAB-A) publishes Phase IIb mesdopetam results in journal
Published by Arron Aatkar, PhD

IRLAB Therapeutics has announced that the results from its Phase IIb clinical trial, evaluating mesdopetam as a potential treatment to address levodopa induced dyskinesias, have been published in the journal Movement Disorders Clinical Practice. The data showed both clinically meaningful and dose-dependent anti-dyskinetic effects of the candidate and, while the primary endpoint was not met (good ON-time), it was encouraging that evaluations for ON-phase dyskinesia, including the Unified Dyskinesia Rating Scale, demonstrated clinically relevant and statistically significant improvements.

Mesdopetam is IRLAB’s lead clinical candidate and, subject to securing a suitable partner, management aims to launch a Phase III programme within 2025.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free